托珠单抗治疗重症活动性类风湿关节炎的疗效

Clinical effect of tocilizumab on patients with severe active rheumatoid arthritis

目的:观察托珠单抗(tocilizumab,TCZ)治疗重症活动性类风湿关节炎(rheumatoid arthritis,RA)的临床疗效及不良反应。方法:12例重症活动性RA接受TCZ治疗,观察并分析TCZ给药前、首次给药后、第3次给药后及第5次给药后各项指标,并记录不良反应发生情况。结果:与治疗前比较,TCZ治疗对休息痛、晨僵、关节压痛数、关节肿胀数、患者对疾病活动性总体评价、血沉、C反应蛋白、疾病活动性评分(DAS28)等指标均有不同程度地改善(P<0.05),无严重不良反应。结论:TCZ能迅速改善重症活动性RA的症状、体征和炎性活动指标,显著改善疾病活动度,且治疗耐受性好。

Objective： To evaluate therapeutic effects severe active rheumatoid arthritis （RA）. and adverse reactions of tocilizumab on patients with Methods： Twelve patients with severe refractory RA were treated with tocilizumab, qqae clinical and laboratory indices and the side effects were recorded after treatment. Results： The clinical and laboratory indices and the disease activity score 28 （DAS28） were observed in all patients, which were significantly improved after TCZ therapy （P〈0.05）, and no obvious adverse reactions were found. Conclusion： Tocilizumab can effectively relieve the symptoms and improve the conditions of severe active RA.